Baker McKenzie has advised Sino Biopharmaceutical Limited (“Sino Biopharm”) on its strategic partnership with Boehringer Ingelheim to bring Boehringer Ingelheim’s innovative cancer therapies to the mainland China market.
According to the strategic collaboration agreement, the two companies will jointly develop and commercialize a number of Boehringer’s innovative oncology products that are in the late stages of clinical development, including but not limited to brigimadlin, zongertinib and DLL3/CD3 T-cell engager. For more details about the deal, please refer to the company’s announcement.
The cross-office, cross-practice deal team was led by Julia Schieber (partner, IP) of Baker McKenzie and Yilan Yang (senior counsel, IP) of FenXun, the joint operation partner of Baker McKenzie in China. Other members of the team include Derek Poon (partner, M&A/ PE), Associates Wenting Lu*, Sunny Li* of Baker McKenzie in Hong Kong, Chris Jiang (Counsel, M&A) of FenXun, as well as lawyers from across the Firm’s Zurich, Hong Kong, Shanghai, Beijing, Dubai and London offices.
Commenting on the deal, Julia said, ”We are very pleased to have assisted Sino Biopharm on this strategic transaction, which marks a milestone in the company’s journey to improve China’s access to innovative, international drugs. This transaction demonstrates our unrivalled ability to assist companies across multi-faceted issues in complex cross-border transaction and our deep knowledge and experience in the healthcare and life sciences sectors.”
Derek added: “As Sino Biopharm continues with its pursuit of “In China for Global” and “In Global for Global” strategy, we look forward to continuing to support the company and help them connect with business partners and opportunities worldwide, something which Baker McKenzie has been doing for all our clients for the last 75 years.”
Baker McKenzie's Healthcare & Life Sciences group is one of the largest of any international law firm comprising more than 800 lawyers in 45 countries. The team, which includes professionals with scientific backgrounds, is recognized by clients and industry peers for the premium quality advice it provides across all aspects of legal issues that healthcare and life sciences, biotechs and medical devices companies face, including M&A, reorganizations; carve-outs; divestitures; collaborations; licensing and other commercial arrangements; tax; regulatory compliance; data and technology; IP; advertising and promotion; employment and compensation; ESG and sustainability; competition; supply chains; trade; product safety and liability; and litigation.
‘* registered foreign lawyer
According to the strategic collaboration agreement, the two companies will jointly develop and commercialize a number of Boehringer’s innovative oncology products that are in the late stages of clinical development, including but not limited to brigimadlin, zongertinib and DLL3/CD3 T-cell engager. For more details about the deal, please refer to the company’s announcement.
The cross-office, cross-practice deal team was led by Julia Schieber (partner, IP) of Baker McKenzie and Yilan Yang (senior counsel, IP) of FenXun, the joint operation partner of Baker McKenzie in China. Other members of the team include Derek Poon (partner, M&A/ PE), Associates Wenting Lu*, Sunny Li* of Baker McKenzie in Hong Kong, Chris Jiang (Counsel, M&A) of FenXun, as well as lawyers from across the Firm’s Zurich, Hong Kong, Shanghai, Beijing, Dubai and London offices.
Commenting on the deal, Julia said, ”We are very pleased to have assisted Sino Biopharm on this strategic transaction, which marks a milestone in the company’s journey to improve China’s access to innovative, international drugs. This transaction demonstrates our unrivalled ability to assist companies across multi-faceted issues in complex cross-border transaction and our deep knowledge and experience in the healthcare and life sciences sectors.”
Derek added: “As Sino Biopharm continues with its pursuit of “In China for Global” and “In Global for Global” strategy, we look forward to continuing to support the company and help them connect with business partners and opportunities worldwide, something which Baker McKenzie has been doing for all our clients for the last 75 years.”
Baker McKenzie's Healthcare & Life Sciences group is one of the largest of any international law firm comprising more than 800 lawyers in 45 countries. The team, which includes professionals with scientific backgrounds, is recognized by clients and industry peers for the premium quality advice it provides across all aspects of legal issues that healthcare and life sciences, biotechs and medical devices companies face, including M&A, reorganizations; carve-outs; divestitures; collaborations; licensing and other commercial arrangements; tax; regulatory compliance; data and technology; IP; advertising and promotion; employment and compensation; ESG and sustainability; competition; supply chains; trade; product safety and liability; and litigation.
‘* registered foreign lawyer
Explore Our Newsroom